TN2013000353A1 - Dérivés de fluoro-pyridinone utiles comme agents antibactériens - Google Patents

Dérivés de fluoro-pyridinone utiles comme agents antibactériens

Info

Publication number
TN2013000353A1
TN2013000353A1 TNP2013000353A TN2013000353A TN2013000353A1 TN 2013000353 A1 TN2013000353 A1 TN 2013000353A1 TN P2013000353 A TNP2013000353 A TN P2013000353A TN 2013000353 A TN2013000353 A TN 2013000353A TN 2013000353 A1 TN2013000353 A1 TN 2013000353A1
Authority
TN
Tunisia
Prior art keywords
fluoro
antibacterial agents
derivatives useful
pyridinone derivatives
pyridinone
Prior art date
Application number
TNP2013000353A
Other languages
English (en)
Inventor
Matthew Frank Brown
Ye Che
Michael Joseph Melnick
Justin Ian Montgomery
Mark Stephen Plummer
Loren Michael Price
Usa Reilly
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of TN2013000353A1 publication Critical patent/TN2013000353A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

La présente invention concerne une nouvelle classe de dérivés d'acide hydroxamique, leur utilisation en tant qu'inhibiteurs de LpxC et, plus spécifiquement, leur utilisation pour traiter des infections bactériennes.
TNP2013000353A 2011-03-07 2013-08-27 Dérivés de fluoro-pyridinone utiles comme agents antibactériens TN2013000353A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161449825P 2011-03-07 2011-03-07
PCT/IB2012/050812 WO2012120397A1 (fr) 2011-03-07 2012-02-22 Dérivés de fluoro-pyridinone utiles en tant qu'agents antibactériens

Publications (1)

Publication Number Publication Date
TN2013000353A1 true TN2013000353A1 (fr) 2015-01-20

Family

ID=45841548

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2013000353A TN2013000353A1 (fr) 2011-03-07 2013-08-27 Dérivés de fluoro-pyridinone utiles comme agents antibactériens

Country Status (33)

Country Link
US (2) US8624034B2 (fr)
EP (1) EP2683689B1 (fr)
JP (1) JP5620020B2 (fr)
KR (1) KR101593288B1 (fr)
CN (2) CN104529883A (fr)
AP (1) AP3336A (fr)
AR (1) AR085615A1 (fr)
AU (1) AU2012226473B8 (fr)
BR (1) BR112013022536B1 (fr)
CA (1) CA2828337C (fr)
CL (1) CL2013002417A1 (fr)
CO (1) CO6761338A2 (fr)
CR (1) CR20130403A (fr)
CU (1) CU20130117A7 (fr)
DO (1) DOP2013000200A (fr)
EA (1) EA024782B1 (fr)
EC (1) ECSP13012928A (fr)
ES (1) ES2626457T3 (fr)
GE (1) GEP20156370B (fr)
GT (1) GT201300213A (fr)
HK (2) HK1209734A1 (fr)
IL (1) IL228100A0 (fr)
MA (1) MA34963B1 (fr)
MX (1) MX341977B (fr)
NI (1) NI201300077A (fr)
PE (1) PE20140397A1 (fr)
SG (1) SG192766A1 (fr)
TN (1) TN2013000353A1 (fr)
TW (1) TWI453197B (fr)
UA (1) UA107423C2 (fr)
UY (1) UY33936A (fr)
WO (1) WO2012120397A1 (fr)
ZA (1) ZA201306515B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2334636A2 (fr) 2008-09-19 2011-06-22 Pfizer Inc. Dérivés d'acide hydroxamique utiles comme agents antibactériens
CA2782453C (fr) 2009-12-16 2015-11-24 Matthew Frank Brown Derives d'acide hydroxamique a liaison n, utiles comme agents antibacteriens
MX341977B (es) 2011-03-07 2016-09-07 Pfizer Derivados de fluoro-piridinona utiles como agentes antibacterianos.
CA2830920C (fr) 2011-04-08 2015-07-14 Pfizer Inc. Derives d'isoxazole utiles en tant qu'agents antibacteriens
CA2830866A1 (fr) 2011-04-08 2012-10-11 Pfizer Inc. Derives d'imidazole, de pyrazole et de triazole, utiles en tant qu'agents antibacteriens
AR097617A1 (es) * 2013-09-13 2016-04-06 Actelion Pharmaceuticals Ltd Derivados antibacterianos del 2h-indazol
WO2015085238A1 (fr) * 2013-12-05 2015-06-11 The Regents Of The University Of California, A California Corporation Inhibiteurs de lpxc
EP3083567B1 (fr) * 2013-12-19 2018-03-07 Idorsia Pharmaceuticals Ltd Dérivés de 1h-indazole et de 1h-indole antibactériens
AR099612A1 (es) 2014-03-04 2016-08-03 Actelion Pharmaceuticals Ltd Derivados antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona
JP6514716B2 (ja) 2014-04-22 2019-05-15 ノバルティス アーゲー ＬｐｘＣ阻害剤としてのイソオキサゾリンヒドロキサム酸誘導体
CA2948077A1 (fr) 2014-05-16 2015-11-19 Actelion Pharmaceuticals Ltd Derives antibacteriens de quinazoline-4(3h)-one
DK3152199T3 (en) 2014-06-03 2018-11-26 Idorsia Pharmaceuticals Ltd PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS
AR102687A1 (es) 2014-11-19 2017-03-15 Actelion Pharmaceuticals Ltd Derivados de benzotiazol antibacterianos
CN107001295B (zh) 2014-12-16 2021-02-02 诺华股份有限公司 作为LpxC抑制剂的异噁唑异羟肟酸化合物
CN104876883B (zh) * 2015-06-05 2017-11-28 安徽联创生物医药股份有限公司 抗失眠药物苏沃雷生中间体的合成方法
AR105646A1 (es) 2015-08-11 2017-10-25 Actelion Pharmaceuticals Ltd Agentes antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituida
AR105889A1 (es) 2015-09-03 2017-11-22 Actelion Pharmaceuticals Ltd Compuestos antibacterianos 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituidos
CA3026356A1 (fr) 2016-06-14 2017-12-21 Novartis Ag Forme cristalline du (r)-4-(5-(cyclopropylethynyl)isoxazol-3-yl)-n-hydroxy-2-methyl-2-(methylsulfonyl)butanamide en tant qu'agent antibacterien
CA3046846A1 (fr) 2016-12-16 2018-06-21 Idorsia Pharmaceuticals Ltd Combinaison pharmaceutique comprenant un bloqueur de canal calcique de type t
TWI808960B (zh) 2017-02-06 2023-07-21 瑞士商愛杜西亞製藥有限公司 用於合成1-芳基-1-三氟甲基環丙烷之新穎方法
WO2019175828A1 (fr) * 2018-03-15 2019-09-19 Pfizer Inc. Phosphates et boronates de fluoro-pyridinone utiles en tant qu'agents antibactériens
MX2020009584A (es) * 2018-03-15 2020-10-05 Pfizer Fosfatos y boronatos de piridinona y pirimidinona utiles como agentes antibacterianos.
CN110699312B (zh) * 2019-11-28 2022-08-12 西北农林科技大学 一种猪种布鲁氏菌bi-1基因缺失菌株及其构建方法和应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769461A (en) 1986-09-16 1988-09-06 American Home Products Corporation Quinolinyl benzene hydroxamic acids as anti-inflammatory/antiallergic agents
US5110831A (en) 1990-11-30 1992-05-05 Du Pont Merck Pharmaceutical Company Vinylogous hydroxamic acids and derivatives thereof as 5-lipoxygenase inhibitors
KR100600518B1 (ko) 1998-02-07 2006-07-13 브리티쉬 바이오테크 파마슈티칼스 리미티드 항균제
GB9925470D0 (en) 1999-10-27 1999-12-29 Smithkline Beecham Plc Novel compounds
WO2002074298A1 (fr) 2001-03-21 2002-09-26 Ono Pharmaceutical Co., Ltd. Inhibiteurs de production d'il-6
ES2180456B1 (es) 2001-07-20 2004-05-01 Laboratorios S.A.L.V.A.T., S.A. Isoxazoles sustituidos y su utilizacion como antibioticos.
GEP20063937B (en) * 2002-02-14 2006-10-10 Pharmacia Corp Substituted pyridinones as modulators of p38 map kinase
CN1777577B (zh) 2003-01-08 2011-07-06 诺华疫苗和诊断公司 抗菌剂
GB0302431D0 (en) 2003-01-30 2003-03-05 Glaxo Group Ltd Novel compounds
US7495006B2 (en) 2004-12-10 2009-02-24 Emory University 2′ and 3′-substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation
WO2006118155A1 (fr) 2005-04-27 2006-11-09 Ishihara Sangyo Kaisha, Ltd. Derive de biphenyle ou son sel, et bactericide pour un usage en agriculture et en horticulture le contenant en tant que principe actif
WO2006124897A2 (fr) 2005-05-13 2006-11-23 Lexicon Genetics Incorporated Procedes et compositions d'amelioration de la cognition
JP2009520695A (ja) * 2005-12-15 2009-05-28 ヴィキュロン ファーマシューティカルズ インコーポレイテッド 抗菌活性を有するｎ−ヒドロキシアミド誘導体
US20080085893A1 (en) 2006-10-06 2008-04-10 Shyh-Ming Yang Matrix metalloprotease inhibitors
WO2009008905A1 (fr) 2007-02-01 2009-01-15 Panthera Biopharma, Llc. Dérivés d'acide hydroxamique d'acides phénoxy-acétiques et analogues utilisés comme agents thérapeutiques pour traiter un empoisonnement par le charbon
JP5227304B2 (ja) 2007-02-28 2013-07-03 大正製薬株式会社 新規なヒドロキサム酸誘導体
WO2008115262A2 (fr) 2007-03-20 2008-09-25 Curis, Inc. Inhibiteurs de hsp90 contenant une fraction de liaison de zinc
CN101239978A (zh) * 2008-03-05 2008-08-13 南方医科大学 一种咪唑并吡啶类化合物
AU2009279949A1 (en) * 2008-08-04 2010-02-11 Merck Sharp & Dohme Corp. Urea derivatives as antibacterial agents
JP5455913B2 (ja) 2008-08-27 2014-03-26 大正製薬株式会社 ナフチリジン−ｎ−オキシドを有する新規ヒドロキサム酸誘導体
US8372885B2 (en) 2008-09-17 2013-02-12 Novartis Ag Organic compounds and their uses
EP2334636A2 (fr) 2008-09-19 2011-06-22 Pfizer Inc. Dérivés d'acide hydroxamique utiles comme agents antibactériens
WO2010100475A1 (fr) 2009-03-02 2010-09-10 Astrazeneca Ab Dérivés de l'acide hydroxamique en tant qu'agents contre des bactéries à gram négatif
EP2443121A2 (fr) * 2009-06-16 2012-04-25 Schering Corporation Modulateurs de gamma sécrétase
US20120245158A1 (en) * 2009-06-16 2012-09-27 Xianhai Huang Gamma secretase modulators
CA2782453C (fr) * 2009-12-16 2015-11-24 Matthew Frank Brown Derives d'acide hydroxamique a liaison n, utiles comme agents antibacteriens
MX341977B (es) 2011-03-07 2016-09-07 Pfizer Derivados de fluoro-piridinona utiles como agentes antibacterianos.
CA2830920C (fr) 2011-04-08 2015-07-14 Pfizer Inc. Derives d'isoxazole utiles en tant qu'agents antibacteriens
CA2830866A1 (fr) 2011-04-08 2012-10-11 Pfizer Inc. Derives d'imidazole, de pyrazole et de triazole, utiles en tant qu'agents antibacteriens

Also Published As

Publication number Publication date
AP3336A (en) 2015-07-31
BR112013022536A2 (pt) 2016-11-29
US8624034B2 (en) 2014-01-07
US8779148B2 (en) 2014-07-15
MX2013010276A (es) 2013-10-01
MA34963B1 (fr) 2014-03-01
CN104529883A (zh) 2015-04-22
CU20130117A7 (es) 2013-10-29
PE20140397A1 (es) 2014-03-28
JP5620020B2 (ja) 2014-11-05
EP2683689B1 (fr) 2017-04-12
CN103443079A (zh) 2013-12-11
ZA201306515B (en) 2014-05-28
CL2013002417A1 (es) 2013-12-13
NI201300077A (es) 2014-01-07
TWI453197B (zh) 2014-09-21
CA2828337A1 (fr) 2012-09-13
NZ614205A (en) 2014-06-27
GEP20156370B (en) 2015-09-25
ES2626457T3 (es) 2017-07-25
AR085615A1 (es) 2013-10-16
MX341977B (es) 2016-09-07
AU2012226473B8 (en) 2015-10-15
EP2683689A1 (fr) 2014-01-15
CO6761338A2 (es) 2013-09-30
CA2828337C (fr) 2016-05-03
GT201300213A (es) 2014-06-06
ECSP13012928A (es) 2013-11-29
TW201249798A (en) 2012-12-16
BR112013022536B1 (pt) 2020-05-26
CR20130403A (es) 2013-09-18
UA107423C2 (en) 2014-12-25
IL228100A0 (en) 2013-09-30
AU2012226473A1 (en) 2013-09-05
EA024782B1 (ru) 2016-10-31
EA201391072A1 (ru) 2014-02-28
US20120232083A1 (en) 2012-09-13
CN103443079B (zh) 2015-06-03
HK1209734A1 (en) 2016-04-08
KR101593288B1 (ko) 2016-02-11
DOP2013000200A (es) 2014-06-15
KR20130131459A (ko) 2013-12-03
SG192766A1 (en) 2013-09-30
JP2014507464A (ja) 2014-03-27
UY33936A (es) 2012-10-31
WO2012120397A1 (fr) 2012-09-13
US20140057919A1 (en) 2014-02-27
AU2012226473B2 (en) 2015-06-11
HK1191951A1 (en) 2014-08-08
AP2013007074A0 (en) 2013-08-31

Similar Documents

Publication Publication Date Title
TN2013000353A1 (fr) Dérivés de fluoro-pyridinone utiles comme agents antibactériens
MA35096B1 (fr) Cyclopropylamines en tant qu'inhibiteurs de lsd1
MA41185B1 (fr) Composés d'acide isoxazole hydroxamique comme inhibiteurs de lpxc
TN2015000347A1 (fr) Azabenzimidazoles servant d'inhibiteurs d'isoenzymes pde4 pour le traitement de troubles du snc et d'autres troubles
MA37519A1 (fr) Composés et compositions pour inhiber l'activité d'abl1, abl2 et bcr-abl1
MA33275B1 (fr) Inhibiteurs de la replication du virus de l'immunodeficience humaine
WO2011045703A3 (fr) Dérivés d'acide hydroxamique à liaison c utiles comme agents antibactériens
MA35452B1 (fr) 3-pyrimidin-4-yl-oxazolidin-2-ones comme inhibiteurs d'idh mutante
EA201290632A1 (ru) Производные бетулина
MX2013011526A (es) Derivados de isoxazol utiles como agentes antibacteriales .
MA35089B1 (fr) Inhibiteurs de la production de leucotrienes de type benzodioxane
MA37142A3 (fr) Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine
UA111770C2 (uk) Інгібітори бромдомену
MA41238B1 (fr) Dérivés 5-[(pipérazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione en tant qu'inhibiteurs d'adamts pour le traitement de l'ostéoarthrit
EA201490747A1 (ru) 1-арилкарбонил-4-оксипиперидиновые соединения, полезные для лечения нейродегенеративных заболеваний
MA35434B1 (fr) Amino-quinazolines en tant qu'inhibiteurs de kinase
EA201391288A1 (ru) Производные пиразолоспирокетонов для применения в качестве ингибиторов ацетил-коа-карбоксилаз
MA35016B1 (fr) Imidazopyridazines en gtant qu'inhibiteurs de la kinase akt
MA39170A1 (fr) Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer
EA200900090A1 (ru) Бензиламины, способ их получения и их применение в качестве противовоспалительных средств
MA35742B1 (fr) Dérivés de n- (4 -quinolinylmethyl) sulfonamide et leur utilisation en tant qu'antihelminthiques
MA42776B1 (fr) Composés utiles pour l'inhibition du ror-gamma-t
MA34098B1 (fr) Utilisation de nouveaux inhibiteurs pan-cdk pour le traitement de tumeurs
MA20150279A1 (fr) (r)-nifuratel, son utilisation pour le traitement d'infections et synthèse de (r) et (s)-nifuratel
TN2012000301A1 (fr) Utilisation du 2,3-dihydroxypropyl dodécanoate pour le traitement de la séborrhée